InsidersTradesSigma
Track the UroGen Pharma Ltd. share price and the full management transaction log of the company, a listed equity based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, UroGen Pharma Ltd. has published 76 reports. Market capitalisation: €2.2bn. The latest transaction was reported on 28 August 2026 (Levée d'options). Among the most active insiders: Schoenberg Mark. Every trade is accessible without an account.
76
Insider Decl.
n/a
Thresholds
€66,753
3 ops.
Buy Volume
€3m
8 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate UroGen Pharma Ltd. Strong Buy (bullish), based on 8 analysts. Average price target: US$60.00.
29Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 28 August 2026
Declarations76 total
2,000 sharesordinary sharesSEC:0001437749-26-029175:0
60,677 shares@ US$47.050.12% mcap34.0% of flowordinary sharesSEC:0001437749-26-028840:0
60,677 shares@ US$47.66620.12% mcap52.2% of flowCOMMONSEC144:0001000275-26-000100
10,000 shares@ US$40.000.017% mcap19.0% of flowOrdinary SharesSEC:0001437749-26-023290:0
10,000 shares@ US$40.00080.017% mcap32.1% of flowCOMMONSEC144:0001000275-26-000093
10,000 shares@ US$35.01430.015% mcap14.3% of flowCOMMONSEC144:0001000275-26-000079
5,222 shares@ US$26.850.0072% mcap5.4% of flowOrdinary sharesSEC144:0001976408-26-000558
2,000 sharesordinary sharesSEC:0001437749-26-006124:0
5,500 sharesOrdinary SharesSEC:0001437749-26-003778:0
1,844 shares@ US$19.691.7% of flowOrdinary SharesSEC:0001437749-26-003040:0
3,333 sharesOrdinary SharesSEC:0001437749-26-002843:0
2,000 sharesordinary sharesSEC:0001437749-25-036576:0
2,000 sharesordinary sharesSEC:0001437749-25-036565:0
2,000 sharesordinary sharesSEC:0001437749-25-036559:0
2,000 sharesordinary sharesSEC:0001437749-25-036555:0
10,000 shares@ US$25.0014.8% of flowOrdinary SharesSEC:0001437749-25-035821:0
4,483 sharesOrdinary SharesSEC:0001437749-25-030772:0
1,667 sharesOrdinary SharesSEC:0001437749-25-028707:0
3,333 sharesOrdinary SharesSEC:0001437749-25-028705:0
10,000 shares@ US$17.6912.3% of flowOrdinary SharesSEC:0001437749-25-026377:0
16,500 sharesOrdinary SharesSEC:0001437749-25-023963:0
10,000 sharesOrdinary SharesSEC:0001437749-25-023961:0
10,000 sharesOrdinary SharesSEC:0001437749-25-020045:0
2,500 sharesOrdinary SharesSEC:0001437749-25-002685:0
25 of 76 declarations
关于 UroGen Pharma Ltd.
UroGen Pharma Ltd. 是一家在美国纳斯达克上市的生物制药公司，股票代码为 URGN（美国）。该公司专注于泌尿科，特别关注泌尿肿瘤学和其他仍有重大未满足医疗需求的特殊泌尿系统疾病。UroGen 成立于 2004 年，总部位于新泽西州普林斯顿，在以色列设有其他业务。从股票投资者的角度来看，该公司最好被理解为一家专业生物技术公司，而非多元化制药集团。（[investors.urogen.com](https://investors.urogen.com/resources/overview/?utm_source=openai)） UroGen 的核心差异化优势是其专有的 RTGel® 逆温水凝胶平台。RTGel 旨在实现药物在泌尿道中的持续局部递送，帮助药物与靶组织接触更长时间。这项技术支撑着已获批产品和未来的管线项目，是公司商业和科学特性的核心。UroGen 将 RTGel 定位为一种改善现有药物治疗效果并支持解剖结构复杂的泌尿系统环境中非手术治疗方案的方式。（[urogen.com](https://www.urogen.com/our-portfolio?utm_source=openai)） 该公司目前的商业产品组合包括 JELMYTO® 和 ZUSDURI™。JELMYTO 是用于肾盂肾盏溶液的丝裂霉素，用于治疗低级别上尿路尿路上皮癌。ZUSDURI，用于膀胱内溶液的丝裂霉素，被 UroGen 描述为首个也是唯一一个获得 FDA 批准用于治疗复发性、低级别、中危非肌层浸润性膀胱癌成年患者的药物。这使得 UroGen 高度专注于一组狭窄的尿路上皮适应症，在这些适应症中，产品差异化、监管独占性和专科医生采用可能比广泛的初级保健规模更重要。（[urogen.com](https://www.urogen.com/our-portfolio?utm_source=openai)） 在竞争方面，UroGen 在泌尿肿瘤学领域占据利基市场。它不试图在广泛的肿瘤学类别中竞争；相反，它针对明确的泌尿系统细分市场，在这些市场中，替代疗法可能具有侵入性、繁琐或不太适合局部递送。该公司的管线策略围绕下一代基于丝裂霉素的资产（如 UGN-103 和 UGN-104）构建，旨在扩展特许经营权并支持 RTGel 平台的生命周期管理。这项管线策略很重要，因为它可以拓宽当前上市产品之外的商业跑道。（[investors.urogen.com](https://investors.urogen.com/news-releases/news-release-details/urogen-announces-zusduritm-launch-track-and-reports-fourth/?utm_source=openai)） 最近的发展尤为重要。2025 年，UroGen 报告了 ZUSDURI 的 FDA 批准和商业发布活动，标志着从以开发为主导的故事向更商业化的重大转变。该公司还继续发布支持其主要项目的临床和持久性数据，同时管理层强调 2026 年是发布轨迹的关键一年。对于投资者而言，关键主题是执行、报销、泌尿科诊所的采用以及公司将其监管里程碑转化为可持续收入增长的能力。（[investors.urogen.com](https://investors.urogen.com/news-releases/news-release-details/urogen-announces-zusduritm-launch-track-and-reports-fourth?utm_source=openai)）
